Insight & Intelligence

More »

GEN News Highlights

More »
November 25, 2013

Cell and Gene Therapy Pioneers Lauded

  • Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc., reports that it will feature a series of “Perspectives” by top pioneers in cell and gene therapy in the 2014 issues of the journal. The series will celebrate Human Gene Therapy’s 25th anniversary next year.

    According to Mary Collins, Ph.D., chair of the award selection committee, a blue-ribbon scientific panel was commissioned to identify the pioneers. “Identifying the pioneers who have made current successes in gene therapy possible was a really interesting process. The committee agreed that a mixture of virologists, technologists, and clinicians had made essential contributions,” says Dr. Collins.

    The Winners of the 12 Pioneer Series Awards are:

    Robin R. Ali, Ph.D., UCL Institute of Ophthalmology;
      Jean Bennett, M.D., Ph.D., Perelman School of Medicine, University of Pennsylvania; and
      William W. Hauswirth, Ph.D., University of Florida College of Medicine
         Nominated for: Gene therapy for eye disorders

    Malcolm K. Brenner, M.D., Ph.D., Baylor College of Medicine
         Nominated for: Cancer gene therapy using gene modified T cells

    Frederic D. Bushman, Ph.D., Perelman School of Medicine, University of Pennsylvania; and
      Christof von Kalle, M.D., Ph.D., National Center for Tumor Diseases, Heidelberg
         Nominated for: Vector integration and tumorigenesis

    Marina Cavazzana, M.D., Ph.D., Paris Descartes University; and
      Adrian J. Thrasher, M.D., Ph.D., UCL Institute of Child Health
         Nominated for: Basic and clinical gene therapy for immunodeficiency disorders

    Ronald G. Crystal, M.D., Weill Cornell Medical College, Cornell University
         Nominated for: Adenoviral vectors/role in translation of gene therapy to clinic

    Zelig Eshhar, Ph.D., Department of Immunology, The Weizmann Institute of Science; and
      Carl H. June, M.D., Perelman School of Medicine, University of Pennsylvania
         Nominated for: CARs for cancer gene therapy/lentiviral gene therapy clinical trials

    Joseph C. Glorioso III, Ph.D., University of Pittsburgh, School of Medicine
         Nominated for: Development of HSV as a vector for gene therapy

    Katherine A. High, M.D., Children's Hospital of Philadelphia;
      Amit C. Nathwani, Ph.D., UCL Cancer Institute;
      Andrew M. Davidoff, M.D., St. Jude Children's Research Hospital; and
      Arthur W. Nienhuis, M.D., St. Jude Children's Research Hospital
         Nominated for: Basic and clinical gene therapy for hemophilia

    A. Dusty Miller, Ph.D., Fred Hutchinson Cancer Research Center, University of Washington; and
      Richard C. Mulligan, Ph.D., Harvard Gene Therapy Initiative, Harvard Institute of Medicine
         Nominated for: Retroviral vectors

    Luigi M. Naldini, M.D., Ph.D., San Raffaele Telethon Institute for Gene Therapy
         Nominated for: Basic and clinical lentiviral vector development and translational gene therapy

    R. Jude Samulski, Ph.D., Gene Therapy Center, University of North Carolina at Chapel Hill
         Nominated for: Basic AAV vector technology

    James M. Wilson, M.D., Ph.D., Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania
         Nominated for: Basic and clinical AAV vector development

Related content